Project Grant K22AI179937
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$159K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...
The National Institute of General Medical Sciences (NIGMS) awarded a $384,896 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of Missouri System. The award will fund research to engineer peptide-based biomodulatory materials that can serve as translational platform technologies for various biomedical applications. Specific objectives include using computational and experimental techniques to develop design rules for micellar...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
This federal Project Grant award of $2,976,652 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore polyamine toxicity and resistance in epidemic bacterial skin pathogens, specifically methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes (Group A Streptococcus). The research aims to understand how polyamines enter and kill these bacteria, and how...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $212,169 to The Johns Hopkins University to advance mentorship and research capabilities related to combating antimicrobial resistant (AMR) infections. The award will enable the principal investigator to enhance their expertise in constructing site-directed mutants of key β-lactamase enzymes and integrating...
This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Washington University to discover novel anti-biofilm agents derived from bacteriophages. The goal is to develop alternative therapies for treating biofilm-associated infections, which are a major challenge for pathogens like Pseudomonas aeruginosa. The research will isolate phages that can overcome biofilm barriers,...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...